Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Prospective, Multinational, Randomized, Open Label Parallel Arm Trial With Blinded Outcome Adjudication Quantifying the Efficacy of SENATOR in Reducing Adverse Drug Reactions in Older Hospitalized Subjects
Brief Summary: Primary Objective: To quantify the benefits of the SENATOR decision support software on the reduction of ADR rates in older hospitalized patients. Secondary Objectives: To evaluate the effect of SENATOR with regard to use of appropriate non-pharmacological therapies in subjects with one core geriatric syndrome.

Tertiary Objectives: to examine the association of SENATOR use with subject survival, morbidity and health related quality of life.

Health Economic Objective: To examine the potential health economic consequences of using SENATOR.

There are two study phases:

Phase I: Prospective multinational, multicentre observational study to estimate the baseline adjudicated medical and surgical ADR rates by clinical subspeciality in 6 international sites.

Phase II: Prospective multinational, multicentre, block randomized, two parallel arm, open label, controlled trial, with blinded outcome ascertainment, of the efficacy of SENATOR software in reducing ADRs in older hospitalized subjects.


Options:
A: Inclusion Criteria:

* Consecutive patients \> 18 years of age admitted to participating internal and family medicine teams during the 1 year study period will be eligible to receive the pharmacist intervention. For the purposes of data analysis, patients with a most responsible or primary diagnosis of HF, COPD, CAP, T2DM, and CAD will be included.

Exclusion Criteria:

* Residence outside the Capital Health catchment
* Admitted for ≤ 2 days
* Palliative care
* Transferred to another team
B: Inclusion Criteria:

* Usual medicine of five drugs or above
* Speak and understand Danish
* Admitted via the Acute Medicine Admission Ward
* Are able to give informed consent

Exclusion Criteria:

* Patients included in a similar study
* Declared terminal
* Suicidal
* In custody
* Isolated at the hospital
* Im- and/or expressive aphasia
* Severe dementia
C: Inclusion Criteria:

1. Provision of informed consent by the patient or legal guardian/next-of-kin
2. Age ≥ 65 years
3. Arrival to hospital within previous 72 hours
4. Admitted as a general medical or surgical on call patient
5. Anticipated in-hospital stay of \> 48 hours,
6. ≥ 3 active (requiring current medication) chronic medical disorders

Exclusion Criteria:

1. Admitted under:

   * Geriatric Medicine
   * Clinical Pharmacology
   * Palliative Medicine
   * Clinical Oncology
   * Hematology
2. Intention of primary team at the time of subject admission to seek a Geriatric Medicine, Clinical Pharmacology or Palliative Medicine in-patient consultation
3. Life expectancy in the opinion of the admitting clinician of \< 3 months
4. Admission directly to an intensive care unit,
5. Admission with primary acute psychiatric illness (excluding delirium)
6. Admission with non-accidental overdose/self-harm
7. Anticipated immediate transfer to alternative non-participating clinical service/hospital
8. Clinical diagnosis of acute Liver failure
9. estimated Glomerular Filtration Rate \<10 ml/min per 1.73 m2
10. Solid organ transplant recipients
11. Patients with malignancy receiving systemic chemotherapy
12. Hospitalized for elective procedure
13. Patient was more than 24 hours in the Emergency Department under the care of a different team to that which finally is in charge of them
14. Patients who are actively participating in another clinical trial
D: Inclusion Criteria:

All patients admitted with acute coronary syndrome (ACS) as the primary reason for hospital admission and use the VA for their usual source of care, defined as having 1 primary care visit within the 12 months prior to hospital admission will be screened for eligibility to participate. ACS is defined as acute myocardial infarction (both ST-elevation MI and non-ST elevation MI) or unstable angina. The presence of acute myocardial infarction will be defined using standard definitions from an international consensus statement, based on the following: a rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit and at least one of the following:

* symptoms of ischemia;
* ECG change indicative of new ischemia (new ST-T changes or new left bundle branch block);
* development of pathological Q waves in the ECG; or
* imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.42 Unstable angina will be defined by presence of ischemic symptoms and ECG changes indicative of new ischemia but without biomarker evidence of myonecrosis (i.e., biomarker elevation) and no evidence of new pathological Q waves, loss of viable myocardium or regional wall motion abnormality.

Exclusion Criteria:

* Patient admitted for primary non-cardiac diagnosis and develop ACS as a secondary condition (e.g. perioperative MI);
* planned discharge to nursing home or skilled nursing facility;
* irreversible, non-cardiac medical condition (e.g. metastatic cancer) likely to affect 6-month survival or ability to execute study protocol;
* lack of telephone/cell phone;
* VA is not primary source of care;
* regularly fill medications at non-VA pharmacy.

Answer: C